+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

From
From
From
From
From
From
From
From
From
From
Blockbuster Oncology Brands - Global Strategic Business Report - Product Thumbnail Image

Blockbuster Oncology Brands - Global Strategic Business Report

  • Report
  • February 2026
  • 284 Pages
  • Global
From
NUT Midline Carcinoma Treatment - Global Strategic Business Report - Product Thumbnail Image

NUT Midline Carcinoma Treatment - Global Strategic Business Report

  • Report
  • February 2026
  • 383 Pages
  • Global
From
Breast Adenocarcinoma Treatment - Global Strategic Business Report - Product Thumbnail Image

Breast Adenocarcinoma Treatment - Global Strategic Business Report

  • Report
  • February 2026
  • 294 Pages
  • Global
From
From
Bile Duct Cancer - Global Strategic Business Report - Product Thumbnail Image

Bile Duct Cancer - Global Strategic Business Report

  • Report
  • February 2026
  • 392 Pages
  • Global
From
From
From
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more